Allergan Plc (AGN)

182.98
0.30 0.16
NYSE : Health Technology
Prev Close 183.28
Open 183.25
Day Low/High 182.36 / 184.78
52 Wk Low/High 142.81 / 207.24
Volume 1.39M
Avg Volume 1.76M
Exchange NYSE
Shares Outstanding 339.44M
Market Cap 61.85B
EPS -13.20
P/E Ratio N/A
Div & Yield 2.88 (1.53%)

Latest News

Allergan Launches Personalized Study Approach For Clinical Research Programs In Inflammatory Bowel Disease

Allergan Launches Personalized Study Approach For Clinical Research Programs In Inflammatory Bowel Disease

- New programs will evaluate the safety and efficacy of brazikumab (an investigational drug) and the potential correlation between biomarkers and patient outcomes with brazikumab

Allergan Receives FDA Clearance To Treat Area Below The Jawline With CoolSculpting®

Allergan Receives FDA Clearance To Treat Area Below The Jawline With CoolSculpting®

DUBLIN, Oct. 4, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the CoolSculpting ® treatment received FDA clearance to treat the submandibular area.

Aegon: Transamerica Settles Universal Life Litigation

Aegon: Transamerica Settles Universal Life Litigation

Aegon's subsidiary Transamerica today announces an agreement that would resolve litigation challenging certain monthly deduction rate adjustments on universal life insurance policies in the United States.

Allergan Launches New JUVÉDERM® IT Campaign Designed To Reach The Next Generation Of Consumers

Allergan Launches New JUVÉDERM® IT Campaign Designed To Reach The Next Generation Of Consumers

Bigger, bolder JUVÉDERM® campaign seeks to make JUVÉDERM® a household name for consumers

Allergan To Report Third Quarter 2018 Earnings And Host Conference Call And Webcast

Allergan To Report Third Quarter 2018 Earnings And Host Conference Call And Webcast

DUBLIN, Oct. 1, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that it intends to release third quarter 2018 financial results on Tuesday, October 30, 2018, prior to the open of U.

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter

Straying from these names could land you in quicksand as the 4th quarter begins.

Allergan And The Allergan Foundation Support Breast Cancer Patients With New Charitable Programs

Allergan And The Allergan Foundation Support Breast Cancer Patients With New Charitable Programs

Allergan Foundation pledges $2,000,000 to support breast health research

Allergan Announces FDA Acceptance Of Supplemental New Drug Application For VRAYLAR® (cariprazine)

Allergan Announces FDA Acceptance Of Supplemental New Drug Application For VRAYLAR® (cariprazine)

- Application Seeks to Expand VRAYLAR Indication to Include the Treatment of Bipolar Depression -

Aegon's US Capital Position To Benefit Significantly From Merger Of Legal Entities

Aegon's US Capital Position To Benefit Significantly From Merger Of Legal Entities

Aegon expects a one-time benefit to capital generation of approximately USD 1 billion as a result of the merger of two legal entities.

A Bullish Options Play on Allergan

A Bullish Options Play on Allergan

Buyout rumors aside, AGN is a name I still find attractive.

Allergan Teams Up With Actor Scott Eastwood To Encourage Recognition Of World Alzheimer's Day On September 21st

Allergan Teams Up With Actor Scott Eastwood To Encourage Recognition Of World Alzheimer's Day On September 21st

The company and actor join forces to pay homage to those affected by Alzheimer's Disease

Aegon Announces Purchase Of Shares To Neutralize 2018 Interim Stock Dividend

Aegon Announces Purchase Of Shares To Neutralize 2018 Interim Stock Dividend

Aegon will repurchase 24,133,950 common shares to neutralize the dilutive effect of the 2018 interim stock dividend.

Allergan Announces Results Of Higher Dose BOTOX® Cosmetic (onabotulinumtoxinA) For The Treatment Of Moderate To Severe Glabellar Lines

Allergan Announces Results Of Higher Dose BOTOX® Cosmetic (onabotulinumtoxinA) For The Treatment Of Moderate To Severe Glabellar Lines

- Study met primary endpoint demonstrating that higher doses of BOTOX® Cosmetic produce greater duration of treatment effect -

Allergan Highlights Key Growth Drivers For Medical Aesthetics

Allergan Highlights Key Growth Drivers For Medical Aesthetics

-- Allergan Medical Aesthetics Business Has Potential to Double by 2025 Driven by Consumer Trends, Geographic Expansion and Innovation --

Allergan To Acquire Bonti Adding New Neurotoxin Programs To Medical Aesthetics Pipeline

Allergan To Acquire Bonti Adding New Neurotoxin Programs To Medical Aesthetics Pipeline

- Acquisition Adds Fast-Acting Neurotoxin Programs with 2 to 4-Week Duration to Allergan's Best-in-Class Medical Aesthetics Portfolio and Pipeline -

Allergan Unveils Spotlyte™, A First-In-Category Digital Hub Designed To Educate Consumers About Medical Aesthetic Treatments

Allergan Unveils Spotlyte™, A First-In-Category Digital Hub Designed To Educate Consumers About Medical Aesthetic Treatments

Spotlyte marks the first launch from Allergan digital ventures unit, Project Moonwalker™

Allergan To Host Medical Aesthetics Day Event On September 14, 2018

Allergan To Host Medical Aesthetics Day Event On September 14, 2018

DUBLIN, Sept. 10, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it will host a Medical Aesthetics Day event and webcast on Friday, September 14, 2018.

The Most Exciting Advance In Skincare Is Here: Introducing The SkinMedica® LUMIVIVE™ System

The Most Exciting Advance In Skincare Is Here: Introducing The SkinMedica® LUMIVIVE™ System

NOVEL, DUAL-ACTING PRODUCT REVITALIZES AND PROTECTS SKIN AGAINST BLUE LIGHT AND ENVIRONMENTAL AGRESSORS AROUND THE CLOCK

Allergan CEO: Botox Is in a Very Strong Position, Despite Growing Competition

Allergan CEO: Botox Is in a Very Strong Position, Despite Growing Competition

The entrance of more competition for Botox Cosmetic could expand the market, the drugmaker's top executive says at the Wells Fargo Healthcare Conference in Boston.

Allergan To Present At The 2018 Morgan Stanley Global Healthcare Conference

Allergan To Present At The 2018 Morgan Stanley Global Healthcare Conference

DUBLIN, Sept. 4, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the 2018 Morgan Stanley Global Healthcare Conference in...

Allergan To Present At The 2018 Wells Fargo Healthcare Conference

Allergan To Present At The 2018 Wells Fargo Healthcare Conference

DUBLIN, Aug. 30, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the 2018 Wells Fargo Healthcare Conference in Boston,...

Allergan Continues Board Refreshment Process

Allergan Continues Board Refreshment Process

-- Director Paul Bisaro to Retire from Allergan Board --

US Subsidiaries Aegon Reach Settlement With SEC

US Subsidiaries Aegon Reach Settlement With SEC

Today, US subsidiaries of Aegon reached a settlement with the Securities and Exchange Commission (SEC) in the matter of the operation and implementation of asset management quantitative models by Aegon's US asset management operations, and related...

Why Large-Cap Pharma Stocks Like Pfizer and Lilly Might Still Have Upside

Why Large-Cap Pharma Stocks Like Pfizer and Lilly Might Still Have Upside

A 'bullish perfect storm of technical factors' is powering the recent strength in large-cap pharma stocks, says Evercore ISI's Rich Ross.

Alibaba's Domestic Focus; Allergan Takes Another Lump -- ICYMI

Alibaba's Domestic Focus; Allergan Takes Another Lump -- ICYMI

Here's what you need to know now for Thursday, Aug. 23.

Allergan Receives Complete Response Letter From The U.S. Food And Drug Administration For Ulipristal Acetate New Drug Application

Allergan Receives Complete Response Letter From The U.S. Food And Drug Administration For Ulipristal Acetate New Drug Application

DUBLIN, Aug. 21, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it received a Complete Response Letter (CRL) from the U.

Allergan Has Finally Made a Base Pattern Traders Can Approach From the Long Side

Allergan Has Finally Made a Base Pattern Traders Can Approach From the Long Side

Let's check out the charts again so see how far this advance might carry.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGN, DSS, ENDP, ICUI, PIH, SPB, SPPI, WAAS, YRD Downgrades: BMA, BRT, ELSE, FRBK, HAE, HSKA, JD, MATW, TCMD, TSG Initiations: ALT, TRTX Read on to get TheStreet Quant Ratings' detailed report:

TheStreet Quant Rating: C (Hold)